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Abstract
 
Dendritic cell (DC) activation by nucleic acid–containing immunoglobulin (Ig)G complexes
has been implicated in systemic lupus erythematosus (SLE) pathogenesis. However, the mecha-
nisms responsible for activation and subsequent disease induction are not completely under-
stood. Here we show that murine DCs are much more effectively activated by immune com-
plexes that contain IgG bound to chromatin than by immune complexes that contain foreign
protein. Activation by these chromatin immune complexes occurs by two distinct pathways.
One pathway involves dual engagement of the Fc receptor Fc
 
 
 
RIII and Toll-like receptor
(TLR)9, whereas the other is TLR9 independent. Furthermore, there is a characteristic cytokine
profile elicited by the chromatin immune complexes that distinguishes this response from that
of conventional TLR ligands, notably the induction of BAFF and the lack of induction of in-
terleukin 12. The data establish a critical role for self-antigen in DC activation and explain how
the innate immune system might drive the adaptive immune response in SLE.
Key words: systemic lupus erythematosus • innate immunity • Fc receptor • BAFF • 
tumor necrosis factor
 
Introduction
 
SLE is characterized by the loss of tolerance to self-antigens
and the consequent production of autoantibodies (1). The
predominant autoantigenic targets are nucleic acid–containing
macromolecules such as chromatin or ribonucleoprotein
particles (1). These autoantigens are continuously being
released or exposed to the extracellular milieu as a result of
apoptosis, but multiple mechanisms normally exist to ensure
that they are rapidly cleared and degraded. A number of
murine models have been developed that have in common
the impaired clearance of apoptotic material. These include
mice deficient in C1q, DNaseI, serum amyloid P component,
or the membrane tyrosine kinase c-mer (2–6). Remarkably,
lupus-like autoimmunity is seen in all these different models,
suggesting that the autoantigens themselves might be driving
the autoimmune response in SLE. The presence of large
amounts of circulating apoptotic cells and nucleosomes in
SLE patients (7, 8), and the identification of C1q or DNase
I genetic deficiencies in certain individuals (9, 10), are con-
sistent with a role for autoantigen in the human disease.
However, a critical factor in the development of autoim-
mune disease is not only the presence of autoantigen, but
also the manner in which the autoantigen is presented to
the immune system.
DCs can induce either T cell tolerance or strong innate
and adaptive immunity to specific antigen (11). In general,
tolerance is initiated when DCs are immature (unactivated),
whereas the initiation of immunity requires an effective
DC maturation (“danger”) signal (12). In the context of
autoimmune disease, DC uptake of apoptotic cells in the
absence of a maturation signal induces tolerance (13).
However, this benign presentation of antigen can be reversed
by the coordinate engagement of Toll-like receptors (TLRs),
CD40, or activating Fc
 
  
 
receptors that provide this matu-
ration signal in vivo (11, 14, 15).
DCs also play a key role in B cell survival and adaptive
antibody responses. The production of the TNF family
 
Address correspondence to Ian R. Rifkin, Boston University School of
Medicine, EBRC 5th
 
 
 
Floor, 650 Albany Street, Boston, MA 02118.
Phone: (617) 638-7325; Fax: (617) 638-7326; email: irifkin@bu.edu
 
Abbreviations used in this paper:
 
 chromatin IC, chromatin immune com-
plex; protein IC, protein immune complex; sODN, phosphorothioate
oligodeoxynucleotide; TLR, Toll-like receptor. 
Dendritic Cell Activation by Chromatin–IgG Complexes
 
1632
ligands BAFF and APRIL are particularly important in this
respect (16, 17). Overexpression of BAFF in transgenic an-
imals leads to lupus-like disease (18, 19), and elevated se-
rum levels of BAFF are found in patients with SLE and
other systemic autoimmune disorders (17, 20). However,
the stimuli that lead to BAFF production in autoimmune
disease are not well understood. Therefore, it is important
to identify ligands that induce BAFF production, particu-
larly in the context of autoimmune disease.
Immune complexes consisting of DNA and anti–double
stranded DNA antibodies isolated from the sera of patients
with SLE can induce plasmacytoid DCs to produce high
levels of IFN-
 
  
 
(21), a cytokine thought to be involved in
SLE pathogenesis (22–24). To eventually limit the conse-
quences of DC activation by these immune complexes, it
will be necessary to understand the mechanisms whereby
this activation occurs. In this regard, we have recently
found that similar chromatin-containing immune com-
plexes can activate IgG2a-specific rheumatoid factor B cells
by a dual receptor mechanism. The IgG autoantibody is
bound and internalized by the B cell receptor and the chro-
matin is then able to engage a TLR, most likely TLR9, in a
cytoplasmic compartment (25). Therefore, we hypothe-
sized that a similar dual receptor mechanism might be op-
erating in DCs, with an Fc
 
  
 
receptor (instead of the B cell
receptor) serving to internalize the chromatin and deliver it
to TLR9. To test this premise, we evaluated the relative ef-
ficiency of chromatin-containing immune complexes on
the activation of DCs derived from wild-type, Fc
 
  
 
recep-
tor–deficient, MyD88-deficient, and TLR9-deficient mice.
These studies have demonstrated both a TLR9-dependent
and -independent pathway in this activation process and
have further revealed distinctive functional properties of
DCs activated via these mechanisms.
 
Materials and Methods
 
Mice.
 
BALB/cJ and Fc
 
 
 
RIII-deficient mice (B6.129P2-
 
Fcgr3
 
tm1Sjv
 
; backcrossed six generations to C57BL/6) were ob-
tained from The Jackson Laboratory. C57BL/6, Fc receptor
common 
 
  
 
chain–deficient (B6.129P2-
 
Fcerg1
 
tm1
 
; backcrossed 12
generations to C57BL/6), and Fc
 
 
 
RII-deficient mice (B6.129-
 
Fcgr2
 
tm1
 
; backcrossed 12 generations to C57BL/6), were obtained
from Taconic. MyD88-deficient mice (backcrossed 12 genera-
tions to C57BL/6; reference 26) and TLR9-deficient mice (back-
crossed three generations to BALB/c; reference 27) were pro-
vided by D. Golenbock (University of Massachusetts, Worcester,
MA) and A. Krieg and P. Payette (Coley Pharmaceuticals, Ot-
tawa, Canada), respectively. All mice were maintained at the Bos-
ton University School of Medicine Laboratory Animal Sciences
Center in accordance with the regulations of the American Asso-
ciation for the Accreditation of Laboratory Animal Care.
 
Preparation of Nucleosomes.
 
We used nucleosomes purified
from bovine thymus as described previously (28) according to the
method of Burlingame and Rubin (29). In brief, nuclei isolated
from bovine thymus (Pel-Freez Biologicals) were physically dis-
rupted and then digested with micrococcal nuclease (Worthing-
ton Biochemical). The digested nucleosome/chromatin frag-
ments were then separated on a 5–30% sucrose gradient to obtain
mononucleosomes, di-nucleosomes, tri-nucleosomes, and higher
oligomers. Nucleosome fraction 4 contained mainly mononu-
cleosomes, whereas nucleosome fraction 7 contained mainly di-
nucleosomes and tri-nucleosomes (28). The nucleosome fractions
were extensively dialyzed against PBS, aliquoted, and frozen at
 
 
 
80
 
 
 
C until used.
 
mAbs and Immune Complexes.
 
The nucleosome-specific
mAbs PL2-3 (IgG2a) and PL2-8 (IgG2b) were provided by M.
Monestier (Temple University, Philadelphia, PA), and the anti-
TNP mAb Hy1.2 (IgG2a) was provided by M. Shlomchik (Yale
University, New Haven, CT). To prepare chromatin-enriched
supernatant, MRL
 
 
 
/
 
  
 
spleen cells at 5 
 
  
 
10
 
6
 
/ml were cultured in
RPMI 1640 with 10% FCS for 48 h. The supernatant was then
collected, 0.2 
 
 
 
M filtered, and stored at 
 
 
 
80
 
 
 
C until needed.
Chromatin is spontaneously released from spleen cells in short-
term in vitro culture (30), and we have demonstrated previously
the ability of PL2-3 to form immune complexes with this re-
leased chromatin (25, 31). Immune complexes comprised of anti-
nucleosome mAb and chromatin (chromatin immune complex
[chromatin IC]) for use in the binding studies shown in Fig. 1, a
and c, were made by premixing PL2-3 (50 
 
 
 
g/ml final concen-
tration) with chromatin-enriched supernatant (12.5% of final vol-
ume) at 37
 
 
 
C for 30 min before addition to the assay. Chromatin
IC for use in the DC activation studies was made by adding the
PL2-3 and PL2-8 (50 
 
 
 
g/ml final concentration) and chromatin-
enriched supernatant (12.5% of total well volume) directly to the
culture wells. Nucleosome/antinucleosome immune complexes
for use in the DC activation studies were made by adding the
PL2-3 (50 
 
 
 
g/ml final concentration) and the various bovine
thymus nucleosome fractions (4 
 
 
 
g/ml final concentration) di-
rectly to the culture wells. Immune complexes comprised of anti-
TNP mAb and TNP-BSA (protein immune complex [protein
IC]) for use in both the binding and activation studies were made
by premixing 50 
 
 
 
g/ml Hy1.2 (50 
 
 
 
g/ml final concentration)
with TNP-BSA (12.5 
 
 
 
g/ml final concentration) at 37
 
 
 
C for 30
min before addition to the assay.
 
DC Preparation.
 
Bone marrow cells were extracted from the
mice and layered onto Lympholyte-M (Cedarlane) density sepa-
ration medium. Cells at the interface were cultured in complete
medium (RPMI 1640 with 10% heat-inactivated FCS, 100 U/ml
penicillin G, 100 
 
 
 
g/ml streptomycin, and 290 
 
 
 
g/ml 
 
l
 
-gluta-
mine) together with 6.7 ng/ml recombinant mouse GM-CSF
(BD Biosciences) and 400 pg/ml recombinant mouse IL-4 (R&D
Systems). On day 6, the cells were collected and the CD11c
 
 
 
cells were isolated using magnetic bead positive selection with
anti-CD11c beads (Miltenyi Biotec). Purity was assessed by flow
cytometry after staining with anti–CD11c-FITC, anti–CD11b-
PE and anti–CD8
 
 
 
-PE mAbs (BD Biosciences). Consistently,
 
 
 
90% of the cells were CD11c
 
  
 
CD11b
 
  
 
CD8
 
 
 
 
 
, in keeping
with a myeloid DC phenotype.
 
Immune Complex Binding to DCs.
 
The immune complexes
(prepared as described above) or the monomeric anti-TNP mAb
Hy1.2, both at 50 
 
 
 
g/ml final antibody concentration, were
added to 10
 
6 
 
DCs from wild-type C57BL/6 mice in 100 
 
 
 
l
Hanks’ balanced salt solution with 5% FCS on ice for 1 h. Cells
were then washed twice and incubated with 500 ng/ml biotin-
conjugated goat F(ab
 
 
 
)
 
2 
 
anti–mouse IgG2a (Southern Biotechnol-
ogy Associates, Inc.) on ice for 1 h. Cells were again washed twice
and incubated with 20 
 
 
 
g/ml streptavidin-PE (Biomeda Corp.)
on ice for 1 h. After two final washes, the cells were analyzed by
flow cytometry to detect the relative amount of bound IgG2a.
 
DC Activation for Cytokine Measurement.
 
3 
 
  
 
10
 
5 
 
DCs were
seeded in 48-well tissue culture plates and cultured in complete 
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medium (as above) with the appropriate ligands in a total well
volume of 600 
 
 
 
l, together with 6.7 ng/ml GM-CSF and 400
pg/ml IL-4. Ligands included the nucleosome-specific mAbs
PL2-3 (IgG2a) and PL2-8 (IgG2b; both at 50 
 
 
 
g/ml), 10 
 
 
 
g/ml
LPS (Sigma-Aldrich), 100 
 
 
 
g/ml poly(I:C) (Sigma-Aldrich), 6
 
 
 
g/ml stimulatory CpG phosphorothioate oligodeoxynucleo-
tide (sODN) 1826 (32), 5
 
 
 
-TCCATGACGTTCCTGACGTT
(Oligo’s Etc), 1 
 
 
 
g/ml of the TLR7 agonist R848 (InvivoGen;
reference 33), and 50 
 
 
 
g/ml protein IC (prepared as described
above). In most experiments, the cells were preactivated before
addition of the ligands with a CD40L–CD8 fusion protein and
supernatant from the anti-CD8 B cell hybridoma 53-6.72 (Amer-
ican Type Culture Collection) as described previously (34) to
amplify the cytokine response (21, 35–37). Chromatin-enriched
supernatants (12.5% of total well volume, prepared as described
above) were added to all wells in the cultures. In certain experi-
ments, 4 
 
 
 
g/ml of the purified nucleosome fractions 4 and 7
(prepared as described above) were added instead of the chroma-
tin-enriched supernatants. In these experiments, the DCs were
not preactivated with the CD40L–CD8 fusion protein and anti-
CD8 B cell hybridoma supernatant. In some experiments, the in-
hibitory CpG sODN 2088 (38), 5
 
 
 
-TCCTGGCGGGGAAGT-
3
 
  
 
(Oligo’s Etc), the control sODN 2138, 5
 
 
 
-TCCATGAGCT-
TCCTGAGCTT-3
 
  
 
(Coley Pharmaceutical Group), the control
sODN 1982 (39), 5
 
 
 
-TCCAGGACTTCTCTCAGGTT-3
 
  
 
(Co-
ley Pharmaceutical Group), or chloroquine (Sigma-Aldrich)
were added to the cultures 30 min before the addition of the
ligands. After 48 h, supernatants were collected and stored at
 
 
 
20
 
 
 
C until cytokine measurements were performed. All anti-
bodies and protein antigens used in the assays had an endotoxin
level 
 
 
 
0.06 EU/ml as measured by Limulus Amebocyte Lysate
ELISA (Bio-Whittaker).
 
DC Costimulatory Molecule Expression.
 
Day 6 DC cultures de-
rived from bone marrows of wild-type BALB/cJ and TLR9-defi-
cient mice were incubated together with 6.7 ng/ml GM-CSF
and 400 pg/ml IL-4 for 24 h together with the following stimuli:
4 
 
 
 
g/ml nucleosome fraction 7 alone, nucleosome/antinucleo-
some immune complexes (50 
 
 
 
g/ml of the antinucleosome mAb
PL2-3 and 4 
 
 
 
g/ml nucleosome fraction 7), protein IC (50 
 
 
 
g/
ml of the anti-TNP mAb Hy1.2 and 12.5 
 
 
 
g/ml TNP-BSA), 10
 
 
 
g/ml LPS, or 6 
 
 
 
g/ml stimulatory CpG sODN 1826. After 24
h of incubation, DCs were double stained with anti–CD11c-PE
(HL3; BD Biosciences) and anti–CD86-FITC (GL1; BD Bio-
sciences) and analyzed by flow cytometry. The DCs used in these
studies were not first purified with anti-CD11c magnetic beads
because use of the beads was found to induce CD86 expression.
 
ELISAs.
 
TNF-
 
  
 
and IL-12 p70 ELISAs were performed ac-
cording to the manufacturer’s instructions (BD Biosciences). The
C1q ELISA was performed as described previously (28). The BAFF
ELISA was performed using monoclonal rat anti–mouse BAFF an-
tibodies and recombinant murine BAFF, which is now available
from Apotech. The level of sensitivity of the assay is 150 pg/ml.
 
Results
 
Chromatin IC, But Not Protein IC, Induces TNF-
 
 
 
.
 
We
began by comparing the stimulatory ability of immune
complexes comprised of chromatin and antinucleosome
mAb (chromatin IC) to isotype-matched immune com-
plexes comprised of TNP-conjugated BSA (TNP-BSA)
and anti-TNP mAb (protein IC). To compare the extent
of immune complex formation in our standard protein IC
and chromatin IC preparations, we determined their rela-
tive ability to bind to C1q, as immune complexes bind C1q
more avidly than monomeric IgG does (40). Both immune
complex preparations bound more strongly to C1q than
uncomplexed IgG did, with the protein IC binding a little
better than the chromatin IC (Fig. 1 a), and thus potentially
consisting of slightly larger complexes.
Next, we evaluated binding of the immune complex
preparations to our DC population. DCs in these studies
consisted of a highly enriched population bearing the char-
acteristic CD11c
 
  
 
CD11b
 
  
 
CD8
 
 
 
  
 
phenotype of myeloid
DCs (Fig. 1 b). Murine bone marrow–derived myeloid
DCs express TLR9 and respond well to TLR9 ligands
such as CpG sODN (27). Because these DCs also express
Figure 1. Chromatin IC and protein IC bind DCs com-
parably. (a) Protein IC (anti-TNP IgG2a mAb plus TNP-
BSA) and chromatin IC (antinucleosome IgG2a mAb plus
spent culture fluid) were tested for immune complex for-
mation in a C1q binding assay and compared with mono-
meric or heat-aggregated (HA) mouse IgG. (b) FACS®
analysis of bone marrow–derived DCs from wild-type
C57BL/6 mice purified with anti-CD11c magnetic beads.
(c) The ability of the monomeric anti-TNP mAb ( -TNP
mAb) and the immune complexes described above to bind
to bone marrow–derived DCs from wild-type C57BL/6
mice was compared by measuring the amount of IgG2a
bound to the cell surface using flow cytometry. 
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Fc
 
 
 
RI, Fc
 
 
 
RII, and Fc
 
 
 
RIII (15, 41), and have been re-
ported to undergo maturation on incubation with protein
ICs (42), they were an appropriate cell type for our studies.
We found that the protein and chromatin IC bound simi-
larly to the DCs and both bound better than uncomplexed
antibody (Fig. 1 c). Thus, it is unlikely that any difference
in stimulatory capacity between the two types of immune
complexes could be attributable to binding efficiency.
We then used TNF-
 
  
 
and IL-12 production as a readout
to compare the functional activities of protein and chroma-
tin IC. DC production of these proinflammatory cytokines
requires a strong activation/maturation signal such as that
mediated by TLR engagement (43). We found that stimu-
lation of the DCs with the conventional TLR3, TLR4,
and TLR9 ligands, poly(I:C), LPS, and hypomethylated
CpG sODN, respectively, resulted in the production of
TNF-
 
  
 
and IL-12 p70 as has been reported by others (Fig.
2 a; references 44 and 45). Protein IC elicited no cytokine
production. Strikingly, however, chromatin IC elicited
levels of TNF-
 
  
 
comparable to conventional TLR ligands
(Fig. 2 a). This was seen with both IgG2a and IgG2b chro-
matin IC (PL2-3 IC and PL2-8 IC, respectively). Also no-
table was the complete absence of IL-12 production in the
chromatin IC cultures (Fig. 2 a). This split cytokine profile,
with selective inhibition of IL-12 but intact TNF-
 
  
 
pro-
duction, is similar to that reported for macrophage activa-
tion by a combination of LPS and Fc
 
  
 
receptor cross-link-
ing reagents (46). Therefore, similar to our observations
with autoreactive rheumatoid factor B cells (25), chromatin
IC can activate DCs under conditions in which protein IC
cannot, and this activation process leads to a cytokine pro-
file distinct from that elicited by conventional TLR ligands.
 
TLR9 Is Involved in Activation by Chromatin IC.
 
To de-
termine whether DC activation by chromatin IC involved
TLR9, we attempted to block the response with known
inhibitors of the TLR9-dependent CpG sODN-driven
signaling pathway. The nuclease-resistant sODN 2088 has
been found to effectively block activation by stimulatory
CpG sODN such as 1826, which is TLR9 dependent, but
does not inhibit activation through either TLR2 or TLR4
(25, 38, 47). The addition of sODN 2088 to the cultures
blocked the chromatin IC induction of TNF-
 
  
 
and also
CpG-mediated cytokine production, but had no effect on
cytokine production induced by the TLR3 ligand poly-
(I:C) or the TLR4 ligand LPS (Fig. 2 a). The inhibitory ef-
fect of sODN 2088 was specific as no inhibition was seen
with the control sODNs 2138 and 1982 (Fig. 2 b). We
observed similar results with chloroquine (Fig. 2 c), an
agent that also inhibits CpG-mediated activation but has
no effect on activation through TLR2 or TLR4 (25, 32,
48). Thus, based on the inhibitor studies, it appeared that
TNF-
 
  
 
production induced by the chromatin IC involved
TLR9 activation.
To confirm these findings, studies were performed with
DCs from both MyD88-deficient mice, which are unre-
sponsive to almost all TLR ligands in terms of cytokine
production, and TLR9-deficient mice (Fig. 3). TNF-
 
 
 
production induced by the chromatin IC was substantially,
Figure 2. Chromatin IC, but
not protein IC, induce TNF- 
production. Bone marrow–
derived DCs from wild-type
C57BL/6  mice were preincu-
bated for 30 min with or with-
out (a) 12  g/ml inhibitory CpG
sODN 2088, (b) sODN 2138,
sODN 1982, sODN 2088 (all at
1   g/ml), and (c) 20  g/ml
chloroquine before the addition
of 50  g/ml protein IC, 50  g/ml
chromatin IC (PL2-3, IgG2a;
PL2-8, IgG2b), 6  g/ml of the
stimulatory CpG sODN 1826,
10  g/ml LPS, and 100  g/ml
poly(I:C). TNF-  and IL-12 p70
concentrations in supernatants
collected after 48 h were deter-
mined by ELISA. The data are
representative of nine (a), three
(b), and three experiments (c).Boulé et al. 1635
but not completely, inhibited in DCs from these mice
compared with wild-type controls. These results not only
demonstrate an important role for TLR9 in DC activation
by chromatin IC, but also indicate the existence of an as yet
unidentified TLR9 and MyD88-independent pathway.
Fc RIII Is Required for Chromatin IC–mediated Activa-
tion. Our original hypothesis was that Fc  receptors
would be required for the uptake of chromatin IC and
their delivery to TLR9 in an intracellular compartment. To
identify the relevant Fc R, we used DCs from various
Fc R-deficient mice. The high affinity Fc RI, which
binds monomeric IgG, and the low affinity Fc RIII, which
binds immune complexes, are stimulatory Fc receptors and
both use the Fc receptor common   chain (49). In the ab-
sence of the Fc receptor common   chain or of Fc RIII
alone, chromatin IC did not induce TNF-  production
(Fig. 4). However, TNF-  production was not inhibited in
DCs from mice deficient in the inhibitory low affinity re-
ceptor Fc RII. Thus, Fc RIII is required for DC activa-
tion by chromatin IC.
Chromatin IC–induced BAFF Production Is TLR9 Indepen-
dent. BAFF is a fundamental survival factor for B cells
made by DCs and other antigen-presenting cells that is im-
plicated in the pathogenesis of SLE and other systemic au-
toimmune disorders (16, 17). Therefore, we tested the
capacity of chromatin IC to induce BAFF production.
Remarkably, it was found that the chromatin IC did in fact
elicit BAFF production, whereas little if any BAFF produc-
tion was elicited by the conventional TLR ligands (Fig. 5).
Protein IC also failed to elicit BAFF production. Even
though DCs derived from the TLR9-deficient mice pro-
duced markedly reduced levels of TNF-  in response to
chromatin IC, they made levels of BAFF that were compa-
rable to wild-type cells. Thus, consistent with the limited
ability of the TLR ligands to elicit BAFF, it was found that
BAFF production induced by the chromatin IC was TLR9
independent and must therefore involve a separate signal-
ing cascade.
Nucleosomes Complexed with Antinucleosome mAb Activate
DCs. The studies above showing chromatin IC–induced
DC activation were performed by allowing the antinucleo-
some mAbs to spontaneously form immune complexes in
cultures containing both spleen cell culture supernatants (as
a source of enriched chromatin), as well as reagents to
cross-link CD40 on the DCs (to amplify the response). All
experimental wells, not just those with antinucleosome
mAb, contained identical amounts of spleen cell culture su-
pernatant and CD40 cross-linking reagents, making it un-
likely that nonchromatin components in the cultures were
responsible for the chromatin IC–induced activation ob-
served. Nevertheless, to more directly demonstrate the re-
quirement for chromatin in DC activation, we performed
experiments using purified calf thymus nucleosomes as a
Figure 3. Chromatin IC–induced TNF-  production involves MyD88
and TLR9. Bone marrow–derived DCs from wild-type C57BL/6 and
MyD88-deficient mice (left), or wild-type BALB/c and TLR9-deficient
mice (right), were cultured with protein IC, chromatin IC (PL2-3,
IgG2a; PL2-8, IgG2b), the stimulatory CpG sODN 1826, and LPS.
TNF-  concentrations in supernatants collected after 48 h were deter-
mined by ELISA. Data represent mean   SEM of three (left) and five
experiments (right).
Figure 4. Fc RIII is required for chromatin IC–induced TNF-  pro-
duction. Bone marrow–derived DCs from wild-type C57BL/6, Fc receptor
common     chain–deficient (FcR  chain    ), Fc RIII-deficient
(Fc RIII / ), and Fc RII-deficient (Fc RII / ) mice were cultured
with protein IC, chromatin IC (PL2-3, IgG2a; PL2-8, IgG2b), the stimu-
latory CpG sODN 1826, and LPS. TNF-  and IL-12 p70 concentrations
in supernatants collected after 48 h were determined by ELISA. The data
are representative of three experiments.
Figure 5. BAFF induction by chromatin IC is TLR9 independent.
Bone marrow–derived DCs from wild-type BALB/c and TLR9-deficient
mice were cultured with protein IC, chromatin IC (PL2-3, IgG2a; PL2-8,
IgG2b), the stimulatory CpG sODN 1826, and LPS. BAFF concentration
in supernatants collected after 48 h was determined by ELISA. The data
are representative of three experiments.Dendritic Cell Activation by Chromatin–IgG Complexes 1636
source of chromatin. We used micrococcal nuclease-
digested nucleosome/chromatin fragments that we further
purified on sucrose gradients to give fractions comprising
different multimers of nucleosome ranging from mainly
mononucleosomes (fraction 4) to mainly di-nucleosomes
and tri-nucleosomes (fraction 7; reference 28). We had
shown that these nucleosome fractions bound specifically
to antinucleosome mAbs, including PL2-3, but not to iso-
type-matched anti-hapten mAbs (28). We added PL2-3
and nucleosome fractions 4 and 7 to the DC cultures in the
absence of spleen cell culture supernatants and in the ab-
sence of CD40 cross-linking reagents, and found that DC
TNF-  production was induced when both PL2-3 and nu-
cleosomes were present together in the cultures, but was
not induced when these immune complex components
were added individually (Fig. 6 a). TNF-  production was
not enhanced by the addition of nucleosomes to cultures
containing protein IC. Remarkably, TNF-   production
induced by the nucleosome–PL2-3 complexes was substan-
tially reduced in DCs from TLR9-deficient mice as com-
pared with wild-type mice (Fig. 6 a).
We also determined the ability of the nucleosome–PL2-3
complexes to increase the expression on DCs of the co-
stimulatory molecule CD86. The nucleosome–PL2-3 com-
plexes, but not the protein IC, induced CD86 up-regula-
tion, although the extent of up-regulation was less than
that seen with either CpG or LPS (Fig. 6 b). The addition
of identical amounts of nucleosome to the protein IC cul-
tures failed to induce CD86 up-regulation (not depicted).
CD86 up-regulation induced by the nucleosome–PL2-3
complexes was observed in DCs from both wild-type and
TLR9-deficient mice, indicating that a TLR9-independent
pathway is sufficient for this effect.
Discussion
Dysregulated DC activation is implicated in the patho-
genesis of SLE (22). Here we show that immune com-
plexes containing self-antigen (chromatin), in contrast to
immune complexes containing conventional protein anti-
gen, activate myeloid DCs through both TLR9-dependent
and -independent pathways.
Figure 6. Nucleosome/antinucleosome complexes activate DCs. (a) Bone marrow–derived DCs from wild-type BALB/c and TLR9-deficient mice
were cultured with the stimulatory CpG sODN 1826, LPS, R848, nucleosome fraction 4 (nucleosome 4; mainly mononucleosomes), nucleosome frac-
tion 7 (nucleosome 7; mainly di-nucleosomes and tri-nucleosomes), the antinucleosome IgG2a mAb PL2-3, PL2-3 and nucleosome 4, PL2-3 and
nucleosome 7, protein IC (anti-TNP IgG2a mAb plus TNP-BSA), and protein IC and nucleosome 4. TNF-  concentrations in supernatants collected
after 24 h were determined by ELISA. The data are representative of three experiments. (b) Day 6 bone marrow–derived DC cultures (not CD11c purified)
from wild-type BALB/c and TLR9-deficient mice were cultured with stimuli as shown. After 24 h of incubation, DCs were double stained with anti–
CD11c-PE and anti–CD86-FITC. CD86 expression of the CD11c  population gate is shown with stimulus-induced staining intensity (black) compared
with staining intensity of the nonstimulated cultures (gray). The data are representative of three experiments.Boulé et al. 1637
The stimulatory capacity of the chromatin IC requires
interaction with the low affinity Fc receptor, Fc RIII.
Other investigators have identified Fc RIII as the critical
IgG receptor mediating disease induction by autoantigen-
containing immune complexes in a mouse rheumatoid ar-
thritis model (50). In general, engagement of Fc RIII by
immune complexes has two major consequences (51). The
first is to initiate signaling cascades via the cytoplasmic
ITAM motif leading to proinflammatory cellular pheno-
types such as degranulation and the transcription of cyto-
kine genes. The second is to mediate the uptake of the im-
mune complexes and their delivery to distinct intracellular
compartments, leading to efficient antigen presentation in
both the MHC class I and II pathways (52). In this study,
Fc RIII engagement alone was insufficient to induce DC
activation as protein IC failed to elicit either cytokine pro-
duction or up-regulation of CD86. Previous studies have
shown variability in the ability of immune complexes to
up-regulate costimulatory molecule expression on DCs
(15, 42, 53, 54). The ability of the chromatin IC and the
nucleosome/antinucleosome complexes, but not the pro-
tein IC, to induce both cytokine production and CD86
up-regulation, indicated that there must be additional acti-
vation pathways dependent on the autoantigen itself. In the
case of the chromatin IC, Fc RIII functions to transport
the complex to an internal compartment where the chro-
matin autoantigen is then able to induce DC activation.
Vertebrate DNA is generally nonstimulatory (55, 56),
unless it is transfected into cells (57–60), supporting the
concept that internalization of chromatin is important for
cell activation. Furthermore, TLR9 is located in an intra-
cellular compartment and therefore it is likely that delivery
of ligand to this intracellular compartment is required for
TLR9 stimulation (61, 62). We investigated the role of
TLR9 in DC activation by chromatin IC because previous
work demonstrated that endogenous chromatin activates
autoreactive B cells if the chromatin is internalized via the
B cell receptor, and that a TLR, most likely TLR9, is re-
quired for this activation (25). This study demonstrates an
important role for TLR9 in DC activation by chromatin
IC and, in addition, points to a TLR9-independent path-
way that contributes to TNF-  production and is required
for BAFF production.
TLR-independent DNA-reactive signaling pathways
have been identified. Drosophila deficient in caspase-acti-
vated DNase and DNase II-like acid DNase accumulate
endogenous intracellular DNA that leads to activation of
innate immunity via the Toll-independent immune defi-
ciency pathway (63). It remains to be established whether
an analogous pathway exists in man, but mice deficient in
caspase-activated DNase and DNase II accumulate DNA
intracellularly and demonstrate innate immune system acti-
vation (64). Our findings are directly relevant to human
SLE because DNA-containing immune complexes purified
from the sera of patients with SLE induce plasmacytoid
DCs to produce IFN-  (21), a cytokine implicated in SLE
pathogenesis (22–24). The effect of DNA-containing im-
mune complexes on other human DC subsets remains to
be determined. However, it is likely that the relative im-
portance of the TLR9-dependent and -independent path-
ways will differ in various DC subsets depending on the
level of TLR9 expression, with TLR9 in humans being
highly expressed in plasmacytoid DCs and less or no ex-
pression found in other subsets (65, 66).
The involvement of TLR9 in DC activation by chroma-
tin IC raises the question of the nature of the mammalian
chromatin able to engage TLR9, as the immune stimula-
tory effects of bacterial DNA mediated through TLR9 are
dependent upon the presence of unmethylated CpG motifs
(55). Bacterial DNA contains many more unmethylated
CpG motifs than vertebrate DNA (67). However, despite
this CpG suppression and methylation compared with bac-
terial DNA, vertebrate DNA nevertheless contains many
unmethylated CpG motifs that could potentially serve as
stimulatory ligands for TLR9 (68). Examples include the
37,000 mouse/45,000 human CpG islands that incorporate
clusters of unmethylated CpG di-nucleotides (69). In addi-
tion to stimulatory CpG motifs, both vertebrate and non-
vertebrate DNA also contain inhibitory motifs capable of
blocking the effect of stimulatory CpG motifs (70). The in-
hibitory activity is critically dependent on base sequence.
Two major nucleotide blocks within the inhibitory motif
are essential for activity, a 5  pyrimidine-rich block and a 3 
poly G block (either a G tetrad or G triplet), with the
length of the intervening sequence between the 5  and 3 
blocks also contributing to inhibitory activity (39). Consis-
tent with this, we observed inhibition of chromatin IC–
induced DC activation with sODN 2088, but not with the
two control sODNs which both lacked a 3  poly G se-
quence (Fig. 2 b). Although the precise mechanism of ac-
tion of the inhibitory motifs has not been defined, sODN
2088 appears to specifically block stimulatory CpG-medi-
ated activation and does not block activation mediated
through TLR2, TLR4, CD40, or the B cell receptor (25,
38, 47). Thus, the ability of sODN 2088 to block chroma-
tin IC–induced DC TNF-  production in our studies is
consistent with a role for TLR9 in this process.
BAFF overexpression in transgenic animals leads to lu-
pus-like autoimmunity, and BAFF serum levels are ele-
vated in patients with SLE and other systemic autoimmune
disorders (18, 19). IFN- , IFN- , CD40L, and IL-10 in-
duce BAFF production by human DCs (16, 71), although
less is known about stimuli that elicit BAFF in murine
DCs. In addition to DCs, BAFF is also made by mono-
cytes, macrophages, and neutrophils (17, 72), but the stim-
uli that induce BAFF production in autoimmunity are not
well defined. The demonstration that chromatin IC can in-
duce BAFF production by myeloid DCs identifies a poten-
tially pivotal mechanism whereby BAFF production could
be chronically elicited in SLE patients with circulating im-
mune complexes.
It is possible that the dual receptor paradigm shown here
for complexed chromatin autoantigens might also apply to
other lupus autoantigens and other cell types. For example,Dendritic Cell Activation by Chromatin–IgG Complexes 1638
small nuclear ribonucleoproteins (RNA/protein particles)
are a common autoantigen specificity in SLE (1) and could
potentially engage either TLR3 or protein kinase R, both
of which can mediate double stranded RNA–induced DC
activation (37, 44). The demonstration that mRNA is an
endogenous ligand for TLR3 supports this possibility (73).
In addition, RNA/protein autoantigens could also engage
TLR7, which has recently been shown to recognize single
stranded RNA and thereby mediate DC activation (74–
76). Intriguingly, it was reported that this recognition by
TLR7 of single stranded RNA is not species specific and
that both self- and viral RNA induce DC activation (74,
75). The predominant intracellular location of TLR3 and
protein kinase R in DCs (37, 77), and the requirement for
normal endosomal acidification in single stranded RNA–
mediated DC activation (75, 76), suggests that internaliza-
tion of the RNA would be required for any such RNA-
induced DC activation in SLE. Although it is established
that immune complexes consisting of DNA and anti–dou-
ble stranded DNA antibodies can induce IFN-  produc-
tion by human plasmacytoid DCs, less is known about the
effect of these complexes on other human cell types. Po-
tential effects on human DCs of the DC1 type or on
neutrophils should be considered, as both express activating
Fc  receptors (49, 78) and can produce BAFF (16, 72).
These possibilities need to be addressed in future studies.
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